Mechanisms of anti-angiogenic tyrosine kinase inhibition on wound healing - The obvious and not so obvious

Cancer Biology and Therapy

Volumn 1, Issue 2, 2002, Pages 127-129

  McCarty, Marya F ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC ANTIBIOTIC; CYCLOHEXANE DERIVATIVE; ENZYME INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; INDOLE DERIVATIVE; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; SEMAXANIB; SESQUITERPENE; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; NOTE; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CYCLOHEXANES; ENZYME INHIBITORS; HUMANS; INDOLES; PROTEIN-TYROSINE KINASES; PYRROLES; SESQUITERPENES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSGLUTAMINASES; WOUND HEALING;

EID: 0036490168     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.56     Document Type: Note

References (20)

1. Ellis LM, Liu W, Fan F, Reinmuth N, Shaheen RM, Jung YD, Ahmad S. Role of angiogenesis inhibitors in cancer treatment. Oncology 2001; 15:39-46. (Pubitemid 33738944)
2. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49:507-21. (Pubitemid 32146414)
3. Kumar R, Yoneda J, Bucana CD, Fidler IJ. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 1998; 12:749-57. (Pubitemid 28133565)
4. Rosen L. Antiangiogenic strategies and agents in clinical trials. The Oncologist 2000; 6:20-7. (Pubitemid 30225453)
5. Miller LL, et al. Efficacy results of a phase I/II study of SU5416 (s)/5-flourouracil (f )/leucovorin (1) relative to results in random subsets of similar patients (pts) froma phase III study of irinotecan (c)/f/lor f/l alone in the therapy of previously untreated metastatic colorectal cancer (mcrc). Proceedings American Society of Clinical Oncology 2001; 20:144:A571.
6. Bergsland E, et al. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV alone in patients with metastatic colorectal cancer. Proceedings American Society of Clinical Oncology 2000; 19:242:A939.
7. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications. Oncologist 2000; 5:11-5. (Pubitemid 30225451)
8. Ellis LM, Gallic Ge. Promiscuous transcription of vascular endothelial growth factor and survival of tumors. J Natl Cancer Inst 2000; 92:1030-1. (Pubitemid 30616474)
9. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9. (Pubitemid 17052899)
10. Gelaw B, Levin S. Wound-induced angiogenesis and its pharmacologic inhibition in a murine model. Surgery 2001; 130:497-501. (Pubitemid 32868463)
11. Yoshida, A, Anand-Apte B, Zetter BR. Differential endothelial migration and proliferation to basic fibroblast groth factor and vascular endothelial growth factor. Growth Factors 1996; 13:57-64.
12. Tanaka H, Taniguchi H, Mugitani T, Koishi Y, Masuyama M, Koyama H, et al. Angiogenesis inhibitor TNP-470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing. Br J Surg 1996; 83:1444-7. (Pubitemid 26342181)
13. Klein SA, Bond SJ, Gupta SC, Yacoub OA, Anderson GL. Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res 1999; 82:268-74. (Pubitemid 29394133)
14. Bond SJ, Klein SA, Anderson GL, Wittliff JL. Interaction of angiogenesis inhibitor TNP-470 with basic fibroblast growth factor receptors. J Surg Res 2000; 92:18-22. (Pubitemid 30437453)
15. Berger AC, Feldman AL, Gnant MF, Kruger EA, Sim BK, Hewitt S, et al. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res 2000; 91:26-31. (Pubitemid 30340891)
16. Bloch W, Huggel K, Sasaki T, Grose R, Bugnon P, Addicks K,et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. Faseb J 2000; 14:2373-6.
17. Streit M, Velasco P, Riccardi L, Spencer L, Brown LF, Janes L, et al. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. Embo J 2000; 19:3272-82. (Pubitemid 30428205)
18. Stout AJ, Gresser I, Thompson WD. Inhibition of wound healing in mice by local interferon alpha/beta injection. Int J Exp Pathol 1993; 74:79-85. (Pubitemid 23076983)
19. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178-89. (Pubitemid 30225181)
20. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279:377-80. (Pubitemid 28063372)